Skin, hair and aesthetics research peptides

This category covers the copper peptide GHK-Cu, the four-component KLOW blend and the melanocortin agonist PT-141, supplied in Canada as lyophilised research material for laboratory use.

GHK-Cu is a copper-binding tripeptide, glycyl-L-histidyl-L-lysine complexed with copper(II). Its literature is largely cell culture and animal work on gene expression and extracellular-matrix proteins, collagen among them, alongside small human studies of topical cosmetic preparations. Those cosmetic studies are a separate literature from lyophilised research material. GHK-Cu is permitted as a topical cosmetic ingredient and is not approved as a medicine.

KLOW combines GHK-Cu, KPV, TB-500 and BPC-157. No study has examined that mixture as such; each component has its own literature, and findings for one do not transfer to the combination.

PT-141 is a melanocortin-3 and melanocortin-4 receptor agonist. Its phase 3 RECONNECT programme led to FDA approval as Vyleesi (bremelanotide) for one indication in premenopausal women. This is research material, not that medicine.

Every lot has a published certificate of analysis, and each product page states CAS number, formula, molecular weight and storage.

Supplied for laboratory research use only, not for human or veterinary use. Certificates for every lot are on testing results.